Aprea logo 445pt.png
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
14 sept. 2021 08h00 HE | Aprea Therapeutics
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
30 août 2021 18h15 HE | Theralase Technologies Inc.
TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research...
Imagin Medical LOGO.jpg
Imagin Medical on Schedule for American Urology Association Demonstration
17 août 2021 08h30 HE | Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the...
20170406 Telix Logo.png
First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
22 juin 2021 19h22 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of...
theralase_logo_destroying_cancer.png
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
11 juin 2021 07h00 HE | Theralase Technologies Inc.
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Releases Q12021 Interim Financial Statements
28 mai 2021 18h58 HE | Theralase Technologies Inc.
TORONTO, May 28, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Imagin Medical LOGO.jpg
IMAGIN MEDICAL REPORTS MANUFACTURING PROGESS
16 mars 2021 08h05 HE | Imagin Medical Inc.
VANCOUVER, B.C. / BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”)...
Imagin Medical LOGO.jpg
IMAGIN MEDICAL CLOSES SECOND TRANCHE OF CONVERTIBLE NOTE OFFERING
18 févr. 2021 08h30 HE | Imagin Medical Inc.
Vancouver, B.C. and Boston, MA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) (“Imagin” or the...
Logo.png
Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years
27 janv. 2021 20h30 HE | DelveInsight Business Research LLP
Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...
Imagin Medical LOGO.jpg
Imagin Medical Engages Torrey Hills Capital
20 janv. 2021 08h30 HE | Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (FSE: DPD2) ("Imagin" or the "Company") is pleased to...